Skip to content

RNTX RNTX Total Equity

Discontinued — last reported Q4 '23

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Gilead Sciences logo
Gilead SciencesGILD
$23.52B+22.7%
AbbVie logo
AbbVieABBV
-$6.66B-569%
CTO
Citius Oncology, Inc.CTOR
$35.27M-1.0%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$57.93M-22.8%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$101.31M+48.7%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: RNTX’s 10-K, filed April 15, 2024, on SEC EDGAR. View the filing →

Ask your AI about RNTX's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's total equity?
RNTX (RNTX) reported total equity of $6.89M in Q4 2023.
How has RNTX's total equity changed year-over-year?
RNTX's total equity decreased by 63.0% year-over-year, from $18.62M to $6.89M.
What is the long-term trend for RNTX's total equity?
Over 3 years (2020 to 2023), RNTX's total equity has grown at a -17.3% compound annual growth rate (CAGR), from $12.16M to $6.89M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.